CA2196165C - Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods - Google Patents
Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods Download PDFInfo
- Publication number
- CA2196165C CA2196165C CA002196165A CA2196165A CA2196165C CA 2196165 C CA2196165 C CA 2196165C CA 002196165 A CA002196165 A CA 002196165A CA 2196165 A CA2196165 A CA 2196165A CA 2196165 C CA2196165 C CA 2196165C
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- solution
- glutaraldehyde
- approximately
- heating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/915—Method or apparatus for preparing biological material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
A method for treating fixed biological tissue inhibits calcification of the biological tissue following implantation thereof in a mammalian body. The method includes placing the biological tissue in contact with glutaraldehyde and then heating the glutaraldehyde.
Alternatively, methods other than heating (e. g., chemical or mechanical means) , for effecting polymerization of the glutaraldehyde may also be utilized. Alternatively, the tissue may be heat treated prior to fixing thereof.
Alternatively, methods other than glutaraldehyde may also be used far fixing the tissue. The biological tissue may be so treated at any time prior to implantation thereof in a mammalian body.
Alternatively, methods other than heating (e. g., chemical or mechanical means) , for effecting polymerization of the glutaraldehyde may also be utilized. Alternatively, the tissue may be heat treated prior to fixing thereof.
Alternatively, methods other than glutaraldehyde may also be used far fixing the tissue. The biological tissue may be so treated at any time prior to implantation thereof in a mammalian body.
Description
01-2'~-9l C2;50P~44 F$ON~ BA~TEk i,AV,' DEFP ~k~J 'TU SI1~ ~, M~BTIRrw'FY
FOi~~/02~
METHODS FOR TRBATING IMhLANTABLE BIOLOt~ICAI. TI8$UE8 TO
MITIGATE TRH C14LCIfIGATION THEREOF AND BIOPR08THETIC
ARTICLES 'TREATED BY SUCK METHODS
Fis~~~ the Iavention The present invention pertains generally to biomedical materials, and more particularly to preserved biological tissues, such as porcine bioprosthetic heart valves, which are implantable in a mammalian body.
Baa~~gpound of the In~e~ t1 ion The prior art has included numerous methods for preserving or fixing biological tissues, to enable such tissues to be subsequently implanted into mammalian bodies. Examples of the types of biological tissues which have heretofore been utilized for surgical implantation include cardiac valves, vascular tissue, skin, dura mater, pericardium, ligaments and tendons.
The term "grafting" as used herein is defined as the implanting or transplanting of any living tissue or organ (See Dorlands Illustrated Medical Dictionary, 27th Edition, W.B. Sounders Co. 1388). Biological tissues which are grafted into the body of a mammal may be xenogeneic (i.e., a xenagraft) or allogeneic (i.e., an allograft) .
The term "bioprosthesis" defines many types of biological tissues che~ioally pretreated before implantation (Carpentier - See Lonescu (editor), Biological Tissue in Heart Valve Replacement, Butterworths, 1972). As opposed to a graft, the fate of a bioprosthesis is based upon the stability of the chefiically treated biological material and not upon cell viabi7.ity or host sell ingrowth. Chemical pretreatment Oi-~'-9i C~:~pPM FRGbrt B~~iFR I,AW DEFT IRZ' TC~ SIM & '~~~li'~RIdEI' P~~~u4;
~~i ~2..
''219 61 b 5 includes the "fixing" or tanning of the biological tissue. Such fixing or tanning of the tissue is accomplished by exposing the tissue to one or more chemical compounds capable of cross-linking molecules within the tissue.
Various chemical compounds have been utilized to fix or cross-link biological tissues including formaldehyde, glutaraldehyde, dialdehyde starch, hexamethylene diisocyanate and certain polyepoxy compounds.
In particular, glutaraldehyde has proven to be relatively physiologically inert and suitable for fixing various biological tissues for subsequent surgical implantation (Carpentier, A., J. Thorac. Cardiovasc.
Surg. 58:467-68 (1969)). In particular, examples of the types of biological tissues which have heretofore been subjected to glutaraldehyde Fixation include porcine bioprosthetic heart valves and bovine pericardial tissues.
Clinical experience has revealed that glutaraldehyde-fixed bioprosthetic tissues may tend to become calcified. Such calcification of glutaraldehyde fixed bioprosthetic tissues has bean reported to occur most predominantly in pediatric patients see, Carpentier et a1. and "Continuing Improvements in Valvular Bioprostheses, J. Thorac Cardiovasc. Surg. 83:27-42, 1982. Such calcification is undesirable in that it may result in deterioration of the mechanical properties of the tissue and/or tissue failure. In view of this, surgeons have opted to implant mechanical cardio-vascular 3o valves into pediatric patients, rather than to utilize glutaraldehyde-preserved porcine valves. However, pediatric patients who receive mechanical valve implants require long term treatment with anticoagulant medications and such anticoagulation is associated with increar~ed risk of hemorrhage.
01-2~-9~ 0~;50P112 rROM BAXTER Lf4V DEPT IRV TO SIM & RICPURNEY P005/021 n ~ -a- ~ ~ 219 616 5 The mechanism by which calcification occurs in glutaraldehyde-fixed bioprosthetic tissue has not been fully elucidated. However, factors which have been thought to influence the rate of calcification include:
a) patient's age b) existing metabolic disorders (i.e., hypercalcemia, diabetes, kidney failure ...) c) dietary factors d) race e) infection f) parenteral calcium administration g) dehydration h) distvrtionjmechanical factors l) inadequate coagulation therapy during initial period following surgical implantation; and j} host tissue chemistry Various efforts have been undertaken to find ways of mitigating calcification of glutaraldehyde fixed bioprosthetic tissue. Included among these calcification mitigation techniques are the methods described in U.S.
Patent No. 4,885,005 (Nashef et al.) SURFACTANT TREATMENT
OF IMPLANTABLE BIOLOGICAL TISSUE TO INHIBIT
CALCIFICATION; U.S. Patent No. 4,648,881 (Carpentier et al.) IMPLANTABLE BIOLOGICAL TISSUE AND PROCESS FOR
PREPARATION THEREOF; U.S. Patent No. 4,976,733 (Girardot) PREVENTION OF PROSTHESIS CALCIFICATION; U.S. Patent No.
4,120,649 (Schechter) TRANSPLANTS; U.S. Patent Na.
5,b02,2566 (Carpentier) CALCIFICATION MITIGATION OF
BIOFROSTHETIC IMPLANTS; EP 103947A2 (Pvllock et a1.) METIiOD FOR INHIBITING MINERALTZATION OF NATURAL TISSUE
DURING IMPLANTATION arid W084/01879 (Nashef et al.) i.--:t ~.2:r'll~i ER~:~?yi BAXTER .,AW DEPS iR'~' Ta ~II~ & MCDUFNEY
PDD6;'~~'.
~"' 2196165 SURFACTANT TREATMENT OF IMPLANTABLE BIOLOGICAL TISSUE TO
INIiI$IT CALCIFICATION.
There remains a need for the development of new methods for inhibiting or mitigating calcification of chemically-fixed biological tissue.
It is postulated that tissue calcification may be minimized by accelerating the polymerization of glutaraldehyde solution coming iota contact with the tissue prior to implantation.
summary o! the Invent on The present invention specifically addresses and alleviates the above-mentioned deficiencies associated with the prior art. More particularly, the present invention comprises a method for treating glutaraldehyde fixed biological tissue or biological tissue fixed with other chemicals so as to ~.nhibit~later calcification of the tissue following implantation of the tissue into a mammalian body. The method comprises placing the biological tissue in contact with glutaraldehyde or another chemical fixative and then heating the glutaraldehyde or other fixative and/or causing the glutaraldehyde or other fixative to be polymerized by thermal, chemical or mechanical means.
Iri the preferred embodiment of the present invention the biological tissue is disposed within a container containing a Q.625% solution of glutaraldehyde comprising approximately 26 mlil glutaraldehyde (25%); approximately 4.863 g/1 HEPES buffer; approximately 2.55 g/1 MgCl2 6H20; and approximately 4.71 g/1 NaCI. The balance of the solution comprises double filtered HZO. Sufficient NaOH is added to adjust the pH to approximately 7.4.
The glutaraldehyde solution is heated to between approximately 35-55°C for approximately 4-22 weeks.
~u-~~-a l o% :5r_;Fr. Fror~ ~~~r:~ Lay J~~~ ~r Tr~ s?~1 ~.: n~~Br~~rr~~~
~o~~?%~~?i r~, ~-~- , ~~ 219 61 b 5 The biological tissue may be heat treated any time prior to implantation thereof within a mammalian body.
For example, the tissue may be~ treated before fixing thereof. Treatment before fixing of the biological tissue merely involves heating it in a saline solution (8 g/1 NaCly or any other physiologic solution at 25-80°C
for a few seconds to 22 weeks. Alternatively, the tissue may be treated during fixing thereof, while the tissue is disposed within a glutaraldehyde solution. Treatment during fixing of the biological tissue merely involves heating of the glutaraldehyde solution to approximately 25-80°C for approximately a few seconds to several months. The preferred range is 35 to 55°C .for 4-22 weeks.
Alternatively, the biological tissue is treated after fixing thereof, and before storage thereof. Such treatment is preferab3.y accomplished while the biological tissue remains within the glutaraldehyde solution utilized during the fixing process and/or is disposed with a glutaraldehyde solution within which the biological tissue is to be stored and again merely comprises heating of the glutaraldehyde solution to approximately 25-80°C for approximately 4--22 weeks.
Alternatively, the biological tissue is treated after storage thereof, typically a short time prior to implantation within a mammalian body. The biological tissue is preferably heated within the glutaraldehyde solution within which it has been stored by merely heating the glutaraldehyde solution to approximately 35 55°C for approximately 4-22 weeks.
Alternatively, the biological tissue is treated during an antxmineralization process by adding glutaraldehyde to the antimineralization solution and heating, preferably to approximately 35-55°C for approximately 4-22 weeks. As those skilled in the art will recognize, various antimineralization processes are utilized to inhibit mineralization of the biological tissue by calcium and various other minerals.
Heating of the glutaraldehyde appears to effect polymerization thereof.
It is believed that the inhibition of calcification is due to the polymerization of glutaraldehyde contained within the biological tissue. KGs such, those skilled in the art will appreciate that various other cross linking agents and other processes, such as light, radiation, or chemicals, which effect polymerization of glutaraldehyde may likewise be utilized in the method for treating biological tissue of the present invention. Thus, various chemical fixatives other than 1o glutaraldehyde and other methods for effecting polymerization of these chemicals and/or glutaraldehyde may be used alone, or in combination with heat, so as to effect polymerization of the chemicals contained within the biological tissue, thereby inhibiting later calcification of the tissue after implantation thereof in a inanunalian body.
~5 The method of inhibiting calcification of fixed biological tissue may be utilized with various different types of biological tissue such as cardiac valves, vascular tissue, skin, dura mater, pericardium, fascias, ligaments, and tendons. Those skilled in the art will realize that this list is not comprehensive in that various other types of biological tissue may also benefit from treatment 2o thereof according to the method of the present invention.
In accordance with an aspect of the invention, a method for treating biological tissue to inhibit calcification following implantation in a mammalian body, the method comprises the steps of:
(a) fixing the tissue in a fixative;
25 (b) disposing the fixed tissue in a solution of fixative; and (c) causing the fixative to polymerize.
In accordance with another aspect of the invention, a bioprosthesis wherein the fixed biological tissue comprises.
a cardiac valve;
30 vascular tissue;
skin;
dura mater;
pericardium;
a ligament; and/or 6a a tendon In accorcance with a further aspect of the invention, a method for treating bovine pericardium tissue or porcine ti slue to inhibit calcification of the tissue following implantatian ire a mammalian t~ody, the method comprising the steps of:
fixing the tissue;
after fixing, heat treating the tissue in a fixative at a temperature of between about :35-55°C for a period of between 4-22 weeks; and sterilizinc the tissue after fixing and prior to heat treating in a solution comprising an alcohol" formaldehyde and polyoxyethylene 20 sorbitan monooleate.
In accordance with another aspect of the invention, a method for treating biological tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
fixing the tissue in a solution comprising a fixative agent;
storing the tissue in a solution comprising a fixative agent;
heating the stored tissue in said solution to a temperature between about 35-55°C; and prior to storing the tissue, sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate.
In accordance with a further aspect of the invention, a method for treating bioiogic~l tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
heat treav:ing the tissue;
sterilizing the tissue separately from the heat treating step by contacting the tissue with a solution comprising are alcohol, formaldehyde and polyoxyethylene 20 sorbitar~ monooleate; and fixing the tissue in a solution comprising a fixative agent.
In accordance with another aspect of the invention, a method for treating biological tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
heat treating the tissue prior to implantation;
6b fixing the tissue in a solution comprising a fixative agent during the heat treating step; and sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 2U sorbitan monooleate, storing the tissue, and wherein the heat treating is performing during storage..
These, as well as other advantages of the present invention will be more apparent from the following description and drawings. It is understood that changes in the specific structure shown and the described may be made within the scope of the claims without departing from the spirit of the invention.
l ; ~ l ',~ ~ .~ 'J ''I~ F RCI~,i E A~.'~E R Lf~~ D E F T . R~' ,~,~ ;,, I M ~
luM~:~ I'R~~E a' -'- ~ 219 616 5 r 8ri~af Descrip~ioa of the Drawings Figure 1 is a flow diagram illustrating the prior art process for preparing biological tissue far implantation within a mammalian body comprising fixing of the biological tissue with a glutaraldehyde solution; and Figure 2 is a flow chart of the preparation of biological tissue for implantation in a mammalian body comprising the method for inhibiting calcification of the biological tissue according to the present invention.
Detailed Description of the deferred Embodiment The detailed description set forth below in connection with the appended drawings is intended as a description of the presently preferred embodiment of the invention, and is not intended to represent the only form in which the present invention may be constructed o~°
utilized. The description sets forth the functions and sequence of steps fvr constructing and operating the invention in connection with the illustrated embodiment.
Tt is to be understood, however, that the same or.
equivalent functions and sequences may be accomplished by different embodiments that are also intended to be encompassed within the spirit and scope of the .invention.
The method for treating glutaraldehyde fixed biological tissue to inhibit calcification thereof following implantation in a mammalian body i.s illustrated in Figure 2 which depicts a flaw chart of the presently preferred embodiment of the invention. Figure 1 depicts a flow chart of the prior art method far preparing biological tissue for implantation within a mammalian body.
Referring now to figure 1, the prior art process for preparing biological tissue for implantation within a mammalian body comprises first harvesting the tissue from :ii-~i-~I ~2;~OPIvL FRChI BANTER i,~,V:' I?EPi 1R~T '"'~ ~IIvI (. r~!~RUFI~EY
P',;'f.0/'~?
-8- ~ 219 616 5 an animal or human cadaver (10). As those skilled in the art will renognize, various different types of tissue are routinely harvested from different animals and/or human cadavers. For example, heart valves are routinely harvested from pigs, pericardium is routinely harvested from cows or pigs, and skin is routinely harvested from human cadavers. Those skilled in the art will further recognize that new tissues are, from time to time, being found to be implantable within a mammalian body.
After harvesting, the biological tissue is rinsed in saline solution, typically for a period of Z-6 hours (12) .
The tissue is next fixed using a o.65%
glutaraldehyde solution at room temperature for at least 3 hours (L4). As is well known, glutaraldehyde effects cross-linking of the proteins, e.g., collagen, within the tissue. Such cross-linking tends to make the tissue more durable and effects preservation thereof. It is known that cross-linked protein exhibits increased resi.stanae to proteolytic cleavage and further that one of the major processes by which circulating blood may destroy tissue is via enzymatic activity which involves unfolding of the protein substrate in order to facilitate enzymatic hydrolysis. Cross-linking of the protein of a tissue makes the tissue resistant to sucri unfolding, and consequently tends to prevent deterioration thereof due to the enzymatic activity of blood.
The tissue is next sterilized, preferably pith an alcohol/formaldehyde solution for 2 hours at room temperature (16). The preferred solution for effecting sterilization of the tissue comprises approximately 12 m1/1 of Tween 80; approximate3y 2.65 gms/1 of MgClz (HzO; approximately 108 m1/1 of formaldEhyde (37~);
approximately 22~ m1/1 of ethyl alcohol (1~0~) and approximately 4.863 gms/1 of HEPES buffer. The balance j'._L~_9~ ~,2;~1?!~ FR~~R' B.q~:'~ER ,A~' DEPl' n5' 'rG ~l~r ~ MCB~'RNEY
Pijl1/G?1 ,~ -g ~~ 219 616 5 of the solution Comprises double filtered HZO. The pH of the solution is typically adjusted to 7.4 via the addition of NaOH. Those skilled in the art will recognize various other sterilization solutions are likewise suitable.
Antimineraiization treatment (I8) is optionally performed so as to inhibit the accumulation of mineral deposits upon the biological tissue after implantation of a maramalian body. As those skilled in the art will recognize, various different antimineralization treatments are utilized so as to prevent the deposition of various different minerals upon the biological tissue.
The tissue is trimmed and any non-biological components are then added thereto (20). For example, it is common to sew a heart valve to a valve holder which aids in the handling thereof and which may additionally function as a mount for the ~ralve when implanted into a mammalian body.
Next, the biological tissue is once again sterilized (22), preferably in an alcohol~formaidehyde solution as discussed above. Since preparation of the biological tissue is substantially complete and the biological tissue will next likely be stored for an extended period of time, a more rigorous sterilization procedure from that previously utilized is typically employed. At this stage, the biological tissue is typically sterilized far approximately 9 hours at 34-38°C.
After sterilization, the biological tissue is stored in glutaraldehyde at room temperature (24).
Referring now to Figure 2, the method for treating glutaraldehyde fixed biological tissue to inhibit calcification thereof following implantation in a mammalian body comprises the additional step of heating preferably when the glutaraldehyde is in contact with D'~-%i-~'I ~2;~OiI~ FR~~~~ E~~.'I'El? ~A~' DEFT' IR~~' ~'0 ~IT! & 1~MEURIdEY
l;;'12i0c' -1°- 219 616 5 the biological tissue, to approximately 35-55°C for approximately 4--22 weeks.
Heating of the biological tissue may be performed at any time after harvesting the tissue from the animal or human cadaver and prior to implanting the tissue within a mammalian body. However, heating of the biological tissue is preferably performed at a paint in the process for preparing the biological tissue when the biological tissue is already disposed within a bath of ZO glutaraldehyde solution, as occurs at various stages of the process according to the prior art. Thus, the method for treating glutaraldehyde fixed biological tissues according to the present invention is preferably performed either during fixing thereof with a ~5 glutaraldehyde solution, immediately after fixing thereof with the glutaraldehyde solution, or alternatively just prior to or after being stored in a glutaraldehyde solution.
As a further alternative, the method for treating 20 glutaraldehyde fixed biological tissues may be performed during antimineralization treatment by adding glutaraldehyde to the antimineralization solution and beating the solution, preferably to approximately 35-55°C
for approximately 4-22 weeks.
25 For example, after fixing tissue using a 0.625%
glutaraldehyde solution at room temperature for at least 3 hours (14), the biological tissue may be heat treated in either the same or different 0.625% glutaraldehyde solution, preferably at approximately 35-55°C for 30 approximately 4-22 weeks (15).
As one of the alternatives discussed above, the biological tissue is fixed arid heat treated simultaneously (13y in the 0.625% glutaraldehyde solution, again preferably at approximately 35-55°C for ~:-%i-~~i ~2:'~DPM FRub: E,Aif~ER ~R.W isLPT IkZ' 'la ~ii~i & h~~.P~iJFNEY
P~~i3;~:'r'' -11- ~~ 19 616 5 approximately 4-22 weeks. Another alternative is to heat the tissue in saline (17) prior to fixation (21).
As the other alternative discussed above, the biological tissue may simultaneously undergo antimineral ization treatment and heat treatment (19).
Glutaraldehyde is added to the antimineralization solution so as to effect the inhibition of calcification of the tissue following implantation in a mammalian body.
Thus, the method for treating fixed biological tissue so as to inhibit calcification thereof following implantation in a mammalian body tends to substantially increase the usable life of such tissue subsequent to implantation in a mammalian body, thereby mitigating the requirement for subsequent tissue rPpiacement. As those skilled in the art will appr~:ciate, such tissue replacement frequently causes substantial trauma to the patient, occasionally resulting in the patient s death.
As such, it is greatly beneficial to be able to either avoid or postpone the need for the replacement of zo implanted biological tissue.
It is understood that the exemplary method for treating glutaraldehyde fixed biological tissue described herein and shown in the drawings represents only a presently preferred embodiment of 'the present invention.
Indeed, various modifications and additions may be made to such embodiment without departing from the spirit and scope of the invention. For example, various fixing agents, such as aldehydes other than glutaraldehyde, may exhibit properties similar to those of glutaraldehyde so as to make them suitable for use in the pxesent invention and, thus, may likewise be utilized. Accordingly, these and other modifications and additions may be obvious to those skilled in the art and may be implemented to adapt the present invention for use in a variety of different applications.
FOi~~/02~
METHODS FOR TRBATING IMhLANTABLE BIOLOt~ICAI. TI8$UE8 TO
MITIGATE TRH C14LCIfIGATION THEREOF AND BIOPR08THETIC
ARTICLES 'TREATED BY SUCK METHODS
Fis~~~ the Iavention The present invention pertains generally to biomedical materials, and more particularly to preserved biological tissues, such as porcine bioprosthetic heart valves, which are implantable in a mammalian body.
Baa~~gpound of the In~e~ t1 ion The prior art has included numerous methods for preserving or fixing biological tissues, to enable such tissues to be subsequently implanted into mammalian bodies. Examples of the types of biological tissues which have heretofore been utilized for surgical implantation include cardiac valves, vascular tissue, skin, dura mater, pericardium, ligaments and tendons.
The term "grafting" as used herein is defined as the implanting or transplanting of any living tissue or organ (See Dorlands Illustrated Medical Dictionary, 27th Edition, W.B. Sounders Co. 1388). Biological tissues which are grafted into the body of a mammal may be xenogeneic (i.e., a xenagraft) or allogeneic (i.e., an allograft) .
The term "bioprosthesis" defines many types of biological tissues che~ioally pretreated before implantation (Carpentier - See Lonescu (editor), Biological Tissue in Heart Valve Replacement, Butterworths, 1972). As opposed to a graft, the fate of a bioprosthesis is based upon the stability of the chefiically treated biological material and not upon cell viabi7.ity or host sell ingrowth. Chemical pretreatment Oi-~'-9i C~:~pPM FRGbrt B~~iFR I,AW DEFT IRZ' TC~ SIM & '~~~li'~RIdEI' P~~~u4;
~~i ~2..
''219 61 b 5 includes the "fixing" or tanning of the biological tissue. Such fixing or tanning of the tissue is accomplished by exposing the tissue to one or more chemical compounds capable of cross-linking molecules within the tissue.
Various chemical compounds have been utilized to fix or cross-link biological tissues including formaldehyde, glutaraldehyde, dialdehyde starch, hexamethylene diisocyanate and certain polyepoxy compounds.
In particular, glutaraldehyde has proven to be relatively physiologically inert and suitable for fixing various biological tissues for subsequent surgical implantation (Carpentier, A., J. Thorac. Cardiovasc.
Surg. 58:467-68 (1969)). In particular, examples of the types of biological tissues which have heretofore been subjected to glutaraldehyde Fixation include porcine bioprosthetic heart valves and bovine pericardial tissues.
Clinical experience has revealed that glutaraldehyde-fixed bioprosthetic tissues may tend to become calcified. Such calcification of glutaraldehyde fixed bioprosthetic tissues has bean reported to occur most predominantly in pediatric patients see, Carpentier et a1. and "Continuing Improvements in Valvular Bioprostheses, J. Thorac Cardiovasc. Surg. 83:27-42, 1982. Such calcification is undesirable in that it may result in deterioration of the mechanical properties of the tissue and/or tissue failure. In view of this, surgeons have opted to implant mechanical cardio-vascular 3o valves into pediatric patients, rather than to utilize glutaraldehyde-preserved porcine valves. However, pediatric patients who receive mechanical valve implants require long term treatment with anticoagulant medications and such anticoagulation is associated with increar~ed risk of hemorrhage.
01-2~-9~ 0~;50P112 rROM BAXTER Lf4V DEPT IRV TO SIM & RICPURNEY P005/021 n ~ -a- ~ ~ 219 616 5 The mechanism by which calcification occurs in glutaraldehyde-fixed bioprosthetic tissue has not been fully elucidated. However, factors which have been thought to influence the rate of calcification include:
a) patient's age b) existing metabolic disorders (i.e., hypercalcemia, diabetes, kidney failure ...) c) dietary factors d) race e) infection f) parenteral calcium administration g) dehydration h) distvrtionjmechanical factors l) inadequate coagulation therapy during initial period following surgical implantation; and j} host tissue chemistry Various efforts have been undertaken to find ways of mitigating calcification of glutaraldehyde fixed bioprosthetic tissue. Included among these calcification mitigation techniques are the methods described in U.S.
Patent No. 4,885,005 (Nashef et al.) SURFACTANT TREATMENT
OF IMPLANTABLE BIOLOGICAL TISSUE TO INHIBIT
CALCIFICATION; U.S. Patent No. 4,648,881 (Carpentier et al.) IMPLANTABLE BIOLOGICAL TISSUE AND PROCESS FOR
PREPARATION THEREOF; U.S. Patent No. 4,976,733 (Girardot) PREVENTION OF PROSTHESIS CALCIFICATION; U.S. Patent No.
4,120,649 (Schechter) TRANSPLANTS; U.S. Patent Na.
5,b02,2566 (Carpentier) CALCIFICATION MITIGATION OF
BIOFROSTHETIC IMPLANTS; EP 103947A2 (Pvllock et a1.) METIiOD FOR INHIBITING MINERALTZATION OF NATURAL TISSUE
DURING IMPLANTATION arid W084/01879 (Nashef et al.) i.--:t ~.2:r'll~i ER~:~?yi BAXTER .,AW DEPS iR'~' Ta ~II~ & MCDUFNEY
PDD6;'~~'.
~"' 2196165 SURFACTANT TREATMENT OF IMPLANTABLE BIOLOGICAL TISSUE TO
INIiI$IT CALCIFICATION.
There remains a need for the development of new methods for inhibiting or mitigating calcification of chemically-fixed biological tissue.
It is postulated that tissue calcification may be minimized by accelerating the polymerization of glutaraldehyde solution coming iota contact with the tissue prior to implantation.
summary o! the Invent on The present invention specifically addresses and alleviates the above-mentioned deficiencies associated with the prior art. More particularly, the present invention comprises a method for treating glutaraldehyde fixed biological tissue or biological tissue fixed with other chemicals so as to ~.nhibit~later calcification of the tissue following implantation of the tissue into a mammalian body. The method comprises placing the biological tissue in contact with glutaraldehyde or another chemical fixative and then heating the glutaraldehyde or other fixative and/or causing the glutaraldehyde or other fixative to be polymerized by thermal, chemical or mechanical means.
Iri the preferred embodiment of the present invention the biological tissue is disposed within a container containing a Q.625% solution of glutaraldehyde comprising approximately 26 mlil glutaraldehyde (25%); approximately 4.863 g/1 HEPES buffer; approximately 2.55 g/1 MgCl2 6H20; and approximately 4.71 g/1 NaCI. The balance of the solution comprises double filtered HZO. Sufficient NaOH is added to adjust the pH to approximately 7.4.
The glutaraldehyde solution is heated to between approximately 35-55°C for approximately 4-22 weeks.
~u-~~-a l o% :5r_;Fr. Fror~ ~~~r:~ Lay J~~~ ~r Tr~ s?~1 ~.: n~~Br~~rr~~~
~o~~?%~~?i r~, ~-~- , ~~ 219 61 b 5 The biological tissue may be heat treated any time prior to implantation thereof within a mammalian body.
For example, the tissue may be~ treated before fixing thereof. Treatment before fixing of the biological tissue merely involves heating it in a saline solution (8 g/1 NaCly or any other physiologic solution at 25-80°C
for a few seconds to 22 weeks. Alternatively, the tissue may be treated during fixing thereof, while the tissue is disposed within a glutaraldehyde solution. Treatment during fixing of the biological tissue merely involves heating of the glutaraldehyde solution to approximately 25-80°C for approximately a few seconds to several months. The preferred range is 35 to 55°C .for 4-22 weeks.
Alternatively, the biological tissue is treated after fixing thereof, and before storage thereof. Such treatment is preferab3.y accomplished while the biological tissue remains within the glutaraldehyde solution utilized during the fixing process and/or is disposed with a glutaraldehyde solution within which the biological tissue is to be stored and again merely comprises heating of the glutaraldehyde solution to approximately 25-80°C for approximately 4--22 weeks.
Alternatively, the biological tissue is treated after storage thereof, typically a short time prior to implantation within a mammalian body. The biological tissue is preferably heated within the glutaraldehyde solution within which it has been stored by merely heating the glutaraldehyde solution to approximately 35 55°C for approximately 4-22 weeks.
Alternatively, the biological tissue is treated during an antxmineralization process by adding glutaraldehyde to the antimineralization solution and heating, preferably to approximately 35-55°C for approximately 4-22 weeks. As those skilled in the art will recognize, various antimineralization processes are utilized to inhibit mineralization of the biological tissue by calcium and various other minerals.
Heating of the glutaraldehyde appears to effect polymerization thereof.
It is believed that the inhibition of calcification is due to the polymerization of glutaraldehyde contained within the biological tissue. KGs such, those skilled in the art will appreciate that various other cross linking agents and other processes, such as light, radiation, or chemicals, which effect polymerization of glutaraldehyde may likewise be utilized in the method for treating biological tissue of the present invention. Thus, various chemical fixatives other than 1o glutaraldehyde and other methods for effecting polymerization of these chemicals and/or glutaraldehyde may be used alone, or in combination with heat, so as to effect polymerization of the chemicals contained within the biological tissue, thereby inhibiting later calcification of the tissue after implantation thereof in a inanunalian body.
~5 The method of inhibiting calcification of fixed biological tissue may be utilized with various different types of biological tissue such as cardiac valves, vascular tissue, skin, dura mater, pericardium, fascias, ligaments, and tendons. Those skilled in the art will realize that this list is not comprehensive in that various other types of biological tissue may also benefit from treatment 2o thereof according to the method of the present invention.
In accordance with an aspect of the invention, a method for treating biological tissue to inhibit calcification following implantation in a mammalian body, the method comprises the steps of:
(a) fixing the tissue in a fixative;
25 (b) disposing the fixed tissue in a solution of fixative; and (c) causing the fixative to polymerize.
In accordance with another aspect of the invention, a bioprosthesis wherein the fixed biological tissue comprises.
a cardiac valve;
30 vascular tissue;
skin;
dura mater;
pericardium;
a ligament; and/or 6a a tendon In accorcance with a further aspect of the invention, a method for treating bovine pericardium tissue or porcine ti slue to inhibit calcification of the tissue following implantatian ire a mammalian t~ody, the method comprising the steps of:
fixing the tissue;
after fixing, heat treating the tissue in a fixative at a temperature of between about :35-55°C for a period of between 4-22 weeks; and sterilizinc the tissue after fixing and prior to heat treating in a solution comprising an alcohol" formaldehyde and polyoxyethylene 20 sorbitan monooleate.
In accordance with another aspect of the invention, a method for treating biological tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
fixing the tissue in a solution comprising a fixative agent;
storing the tissue in a solution comprising a fixative agent;
heating the stored tissue in said solution to a temperature between about 35-55°C; and prior to storing the tissue, sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate.
In accordance with a further aspect of the invention, a method for treating bioiogic~l tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
heat treav:ing the tissue;
sterilizing the tissue separately from the heat treating step by contacting the tissue with a solution comprising are alcohol, formaldehyde and polyoxyethylene 20 sorbitar~ monooleate; and fixing the tissue in a solution comprising a fixative agent.
In accordance with another aspect of the invention, a method for treating biological tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
heat treating the tissue prior to implantation;
6b fixing the tissue in a solution comprising a fixative agent during the heat treating step; and sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 2U sorbitan monooleate, storing the tissue, and wherein the heat treating is performing during storage..
These, as well as other advantages of the present invention will be more apparent from the following description and drawings. It is understood that changes in the specific structure shown and the described may be made within the scope of the claims without departing from the spirit of the invention.
l ; ~ l ',~ ~ .~ 'J ''I~ F RCI~,i E A~.'~E R Lf~~ D E F T . R~' ,~,~ ;,, I M ~
luM~:~ I'R~~E a' -'- ~ 219 616 5 r 8ri~af Descrip~ioa of the Drawings Figure 1 is a flow diagram illustrating the prior art process for preparing biological tissue far implantation within a mammalian body comprising fixing of the biological tissue with a glutaraldehyde solution; and Figure 2 is a flow chart of the preparation of biological tissue for implantation in a mammalian body comprising the method for inhibiting calcification of the biological tissue according to the present invention.
Detailed Description of the deferred Embodiment The detailed description set forth below in connection with the appended drawings is intended as a description of the presently preferred embodiment of the invention, and is not intended to represent the only form in which the present invention may be constructed o~°
utilized. The description sets forth the functions and sequence of steps fvr constructing and operating the invention in connection with the illustrated embodiment.
Tt is to be understood, however, that the same or.
equivalent functions and sequences may be accomplished by different embodiments that are also intended to be encompassed within the spirit and scope of the .invention.
The method for treating glutaraldehyde fixed biological tissue to inhibit calcification thereof following implantation in a mammalian body i.s illustrated in Figure 2 which depicts a flaw chart of the presently preferred embodiment of the invention. Figure 1 depicts a flow chart of the prior art method far preparing biological tissue for implantation within a mammalian body.
Referring now to figure 1, the prior art process for preparing biological tissue for implantation within a mammalian body comprises first harvesting the tissue from :ii-~i-~I ~2;~OPIvL FRChI BANTER i,~,V:' I?EPi 1R~T '"'~ ~IIvI (. r~!~RUFI~EY
P',;'f.0/'~?
-8- ~ 219 616 5 an animal or human cadaver (10). As those skilled in the art will renognize, various different types of tissue are routinely harvested from different animals and/or human cadavers. For example, heart valves are routinely harvested from pigs, pericardium is routinely harvested from cows or pigs, and skin is routinely harvested from human cadavers. Those skilled in the art will further recognize that new tissues are, from time to time, being found to be implantable within a mammalian body.
After harvesting, the biological tissue is rinsed in saline solution, typically for a period of Z-6 hours (12) .
The tissue is next fixed using a o.65%
glutaraldehyde solution at room temperature for at least 3 hours (L4). As is well known, glutaraldehyde effects cross-linking of the proteins, e.g., collagen, within the tissue. Such cross-linking tends to make the tissue more durable and effects preservation thereof. It is known that cross-linked protein exhibits increased resi.stanae to proteolytic cleavage and further that one of the major processes by which circulating blood may destroy tissue is via enzymatic activity which involves unfolding of the protein substrate in order to facilitate enzymatic hydrolysis. Cross-linking of the protein of a tissue makes the tissue resistant to sucri unfolding, and consequently tends to prevent deterioration thereof due to the enzymatic activity of blood.
The tissue is next sterilized, preferably pith an alcohol/formaldehyde solution for 2 hours at room temperature (16). The preferred solution for effecting sterilization of the tissue comprises approximately 12 m1/1 of Tween 80; approximate3y 2.65 gms/1 of MgClz (HzO; approximately 108 m1/1 of formaldEhyde (37~);
approximately 22~ m1/1 of ethyl alcohol (1~0~) and approximately 4.863 gms/1 of HEPES buffer. The balance j'._L~_9~ ~,2;~1?!~ FR~~R' B.q~:'~ER ,A~' DEPl' n5' 'rG ~l~r ~ MCB~'RNEY
Pijl1/G?1 ,~ -g ~~ 219 616 5 of the solution Comprises double filtered HZO. The pH of the solution is typically adjusted to 7.4 via the addition of NaOH. Those skilled in the art will recognize various other sterilization solutions are likewise suitable.
Antimineraiization treatment (I8) is optionally performed so as to inhibit the accumulation of mineral deposits upon the biological tissue after implantation of a maramalian body. As those skilled in the art will recognize, various different antimineralization treatments are utilized so as to prevent the deposition of various different minerals upon the biological tissue.
The tissue is trimmed and any non-biological components are then added thereto (20). For example, it is common to sew a heart valve to a valve holder which aids in the handling thereof and which may additionally function as a mount for the ~ralve when implanted into a mammalian body.
Next, the biological tissue is once again sterilized (22), preferably in an alcohol~formaidehyde solution as discussed above. Since preparation of the biological tissue is substantially complete and the biological tissue will next likely be stored for an extended period of time, a more rigorous sterilization procedure from that previously utilized is typically employed. At this stage, the biological tissue is typically sterilized far approximately 9 hours at 34-38°C.
After sterilization, the biological tissue is stored in glutaraldehyde at room temperature (24).
Referring now to Figure 2, the method for treating glutaraldehyde fixed biological tissue to inhibit calcification thereof following implantation in a mammalian body comprises the additional step of heating preferably when the glutaraldehyde is in contact with D'~-%i-~'I ~2;~OiI~ FR~~~~ E~~.'I'El? ~A~' DEFT' IR~~' ~'0 ~IT! & 1~MEURIdEY
l;;'12i0c' -1°- 219 616 5 the biological tissue, to approximately 35-55°C for approximately 4--22 weeks.
Heating of the biological tissue may be performed at any time after harvesting the tissue from the animal or human cadaver and prior to implanting the tissue within a mammalian body. However, heating of the biological tissue is preferably performed at a paint in the process for preparing the biological tissue when the biological tissue is already disposed within a bath of ZO glutaraldehyde solution, as occurs at various stages of the process according to the prior art. Thus, the method for treating glutaraldehyde fixed biological tissues according to the present invention is preferably performed either during fixing thereof with a ~5 glutaraldehyde solution, immediately after fixing thereof with the glutaraldehyde solution, or alternatively just prior to or after being stored in a glutaraldehyde solution.
As a further alternative, the method for treating 20 glutaraldehyde fixed biological tissues may be performed during antimineralization treatment by adding glutaraldehyde to the antimineralization solution and beating the solution, preferably to approximately 35-55°C
for approximately 4-22 weeks.
25 For example, after fixing tissue using a 0.625%
glutaraldehyde solution at room temperature for at least 3 hours (14), the biological tissue may be heat treated in either the same or different 0.625% glutaraldehyde solution, preferably at approximately 35-55°C for 30 approximately 4-22 weeks (15).
As one of the alternatives discussed above, the biological tissue is fixed arid heat treated simultaneously (13y in the 0.625% glutaraldehyde solution, again preferably at approximately 35-55°C for ~:-%i-~~i ~2:'~DPM FRub: E,Aif~ER ~R.W isLPT IkZ' 'la ~ii~i & h~~.P~iJFNEY
P~~i3;~:'r'' -11- ~~ 19 616 5 approximately 4-22 weeks. Another alternative is to heat the tissue in saline (17) prior to fixation (21).
As the other alternative discussed above, the biological tissue may simultaneously undergo antimineral ization treatment and heat treatment (19).
Glutaraldehyde is added to the antimineralization solution so as to effect the inhibition of calcification of the tissue following implantation in a mammalian body.
Thus, the method for treating fixed biological tissue so as to inhibit calcification thereof following implantation in a mammalian body tends to substantially increase the usable life of such tissue subsequent to implantation in a mammalian body, thereby mitigating the requirement for subsequent tissue rPpiacement. As those skilled in the art will appr~:ciate, such tissue replacement frequently causes substantial trauma to the patient, occasionally resulting in the patient s death.
As such, it is greatly beneficial to be able to either avoid or postpone the need for the replacement of zo implanted biological tissue.
It is understood that the exemplary method for treating glutaraldehyde fixed biological tissue described herein and shown in the drawings represents only a presently preferred embodiment of 'the present invention.
Indeed, various modifications and additions may be made to such embodiment without departing from the spirit and scope of the invention. For example, various fixing agents, such as aldehydes other than glutaraldehyde, may exhibit properties similar to those of glutaraldehyde so as to make them suitable for use in the pxesent invention and, thus, may likewise be utilized. Accordingly, these and other modifications and additions may be obvious to those skilled in the art and may be implemented to adapt the present invention for use in a variety of different applications.
Claims (29)
1. A method for treating bovine pericardium tissue or porcine tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising the steps of:
fixing the tissue;
after fixing, heat treating the tissue in a fixative at a temperature of between about 35-55°C for a period of between 4-22 weeks; and sterilizing the tissue after fixing and prior to heat treating in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate.
fixing the tissue;
after fixing, heat treating the tissue in a fixative at a temperature of between about 35-55°C for a period of between 4-22 weeks; and sterilizing the tissue after fixing and prior to heat treating in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate.
2. The method of claim 1, wherein the step of fixing includes placing the tissue in contact with an approximately 0.625% solution of glutaraldehyde comprising:
a) approximately 26 ml/l glutaraldehyde;
b) approximately 4.863 gel HEPES buffer;
c) approximately 2.65 g/l MgCl2.6H2O;
d) approximately 4.71 g/l NaCl; and e) balance of solution double filtered H2O;
wherein the method further includes adjusting the pH of the solution to approximately 7.4.
a) approximately 26 ml/l glutaraldehyde;
b) approximately 4.863 gel HEPES buffer;
c) approximately 2.65 g/l MgCl2.6H2O;
d) approximately 4.71 g/l NaCl; and e) balance of solution double filtered H2O;
wherein the method further includes adjusting the pH of the solution to approximately 7.4.
3. The method of claim 1, wherein the period is several months.
4. The method of claim 1, comprising the additional step of storing the tissue after sterilizing and then performing the heat treatment during storage.
5. The method of claim 1 wherein the fixative is glutaraldehyde and wherein the heat treating further includes:
placing the tissue in a glutaraldehyde-containing antimineralization solution; and heating the glutaraldehyde-containing antimineralization solution.
placing the tissue in a glutaraldehyde-containing antimineralization solution; and heating the glutaraldehyde-containing antimineralization solution.
6. The method of claim 1 wherein the fixative is glutaraldehyde and wherein the heat treating further includes disposing the tissue in a solution of glutaraldehyde and heating the solution of glutaraldehyde.
7. The method of claim 6, wherein the period is several months.
8. The method of claim 6, wherein the solution of glutaraldehyde is an approximately 0.625% solution of glutaraldehyde comprising:
a) approximately 26 ml/l glutaraldehyde;
b) approximately 4.863 g/l HEPES buffer;
c) approximately 2.65 g/l MgCl2.6H2O;
d) approximately 4.71 g/l NaCl; and e) balance of solution double filtered H2O;
wherein the method further includes adjusting the pH of the solution to approximately 7.4.
a) approximately 26 ml/l glutaraldehyde;
b) approximately 4.863 g/l HEPES buffer;
c) approximately 2.65 g/l MgCl2.6H2O;
d) approximately 4.71 g/l NaCl; and e) balance of solution double filtered H2O;
wherein the method further includes adjusting the pH of the solution to approximately 7.4.
9. A method for treating biological tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
fixing the tissue in a solution comprising a fixative agent;
storing the tissue in a solution comprising a fixative agent;
heating the stored tissue in said solution to a temperature between about 35-55°C; and prior to storing the tissue, sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate.
fixing the tissue in a solution comprising a fixative agent;
storing the tissue in a solution comprising a fixative agent;
heating the stored tissue in said solution to a temperature between about 35-55°C; and prior to storing the tissue, sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate.
10. A method according to claim 0, wherein the tissue is heat treated in a solution selected from the group consisting of a physiologic solution and a glutaraldehyde solution.
11. A method according to claim 9, wherein the step of heating the stored tissue is carried out far a period of time in the range of about a few seconds to 22 weeks.
12. A method according to claim 11, wherein the step of heating the stored tissues is carried out for a period of time in the range of about 4 to 22 weeks.
13. A method for treating biological tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
heat treating the tissue;
sterilizing the tissue separately from the heat treating step by contacting the tissue with a solution comprising are alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate; and fixing the tissue in a solution comprising a fixative agent.
heat treating the tissue;
sterilizing the tissue separately from the heat treating step by contacting the tissue with a solution comprising are alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate; and fixing the tissue in a solution comprising a fixative agent.
14. A method according to claim 13, wherein the tissue is heat treated in a solution selected from the group consisting of a physiologic solution and a glutaraldehyde solution.
15. A method according to claim 13, wherein the step of heating the stored tissue is carried out for a period of time in the range of about a few seconds to 22 weeks.
16. A method according to claim 15, wherein the step of heating the stored tissues is carried out for a period of time in the range of about 4 to 22 weeks.
17. A method according to claim 13, wherein the tissue is heat treated at a temperature in the range of about 35-55°C.
18. A method for treating biological tissue to inhibit calcification of the tissue following implantation in a mammalian body, the method comprising:
heat treating the tissue prior to implantation;
fixing the tissue in a solution comprising a fixative agent during the heat treating step; and sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate, storing the tissue, and wherein the heat treating is performing during storage.
heat treating the tissue prior to implantation;
fixing the tissue in a solution comprising a fixative agent during the heat treating step; and sterilizing the tissue in a solution comprising an alcohol, formaldehyde and polyoxyethylene 20 sorbitan monooleate, storing the tissue, and wherein the heat treating is performing during storage.
19. A method according to claim 18, wherein the tissue is heat treated in a solution selected from the group consisting of a physiologic solution and a glutaraldehyde solution.
20. A method according to claim 18, wherein the step of heating the stored tissue is carried out for a period of time in the range of about a few seconds to 22 weeks.
21. A method according to claim 20, wherein the step of heating the stored tissues is carried out for a period of time in the range of about 4 to 22 weeks.
22. A method according to claim 21, wherein the period is several months.
23. A method according to claim 21, wherein the tissue is heat treated at a temperature in the range of about 35-55°C.
24. A method according to claim 18, wherein the tissue is heat treated at a temperature in the range of about 35~5a°C.
2~. A method according to claim 18, wherein the tissue is fresh prior to heat treating.
26. A method according to claim 18, wherein the tissue is fixed prior to heat treating.
27. A method according to claim 18, wherein the heat treating further includes disposing the tissue in a solution of glutaraldehyde and heating the solution of glutaraldehyde.
28. The method of claim 27, wherein the solution of glutaraldehyde comprises an approximately 0.625% solution of glutaraldehyde comprising:
a) approximately 26 ml/l glutaraldehyde;
b) approximately 4.863 g/l HEPES buffer;
c) approximately 2.65 g/l MgCl2.6H2O;
d) approximately 4.71 g/l NaCI; and e) balance of solution double filtered H2O;
wherein the method further includes adjusting the pH of the solution to approximately 7.4.
a) approximately 26 ml/l glutaraldehyde;
b) approximately 4.863 g/l HEPES buffer;
c) approximately 2.65 g/l MgCl2.6H2O;
d) approximately 4.71 g/l NaCI; and e) balance of solution double filtered H2O;
wherein the method further includes adjusting the pH of the solution to approximately 7.4.
29. A method according to claim 18, wherein the heat treating further includes:
placing the tissue in a glutaraldehyde-containing antimineralization solution; and heating the glutaraldehyde-containing antimineralization solution.
placing the tissue in a glutaraldehyde-containing antimineralization solution; and heating the glutaraldehyde-containing antimineralization solution.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28235894A | 1994-07-29 | 1994-07-29 | |
| US08/282,358 | 1994-07-29 | ||
| PCT/US1995/010001 WO1996004028A1 (en) | 1994-07-29 | 1995-07-25 | Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2196165A1 CA2196165A1 (en) | 1996-02-15 |
| CA2196165C true CA2196165C (en) | 2004-06-08 |
Family
ID=23081148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002196165A Expired - Lifetime CA2196165C (en) | 1994-07-29 | 1995-07-25 | Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6561970B1 (en) |
| EP (1) | EP0804255B1 (en) |
| JP (1) | JP3797673B2 (en) |
| CA (1) | CA2196165C (en) |
| DE (1) | DE69523074T2 (en) |
| WO (1) | WO1996004028A1 (en) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804255B1 (en) | 1994-07-29 | 2001-10-04 | Edwards Lifesciences Corporation | Methods for treating implantable biological tissues to mitigate the calcification thereof |
| US5931969A (en) * | 1994-07-29 | 1999-08-03 | Baxter International Inc. | Methods and apparatuses for treating biological tissue to mitigate calcification |
| USRE40570E1 (en) | 1994-07-29 | 2008-11-11 | Edwards Lifesciences Corporation | Apparatuses and methods for treating biological tissue to mitigate calcification |
| US7001328B1 (en) * | 1994-11-15 | 2006-02-21 | Kenton W. Gregory | Method for using tropoelastin and for producing tropoelastin biomaterials |
| US5782931A (en) * | 1996-07-30 | 1998-07-21 | Baxter International Inc. | Methods for mitigating calcification and improving durability in glutaraldehyde-fixed bioprostheses and articles manufactured by such methods |
| EP0925077B1 (en) * | 1996-08-23 | 2003-10-15 | Cook Biotech, Inc. | Method for obtaining a purified collagen-based matrix from submucosa tissue |
| US6666892B2 (en) * | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| US8716227B2 (en) * | 1996-08-23 | 2014-05-06 | Cook Biotech Incorporated | Graft prosthesis, materials and methods |
| US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
| US8882850B2 (en) * | 1998-12-01 | 2014-11-11 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| US6440164B1 (en) * | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
| US6602286B1 (en) | 2000-10-26 | 2003-08-05 | Ernst Peter Strecker | Implantable valve system |
| US7377938B2 (en) * | 2001-07-19 | 2008-05-27 | The Cleveland Clinic Foundation | Prosthetic cardiac value and method for making same |
| US20030022146A1 (en) * | 2001-07-26 | 2003-01-30 | Cunanan Crystal M. | Oxidized bioprosthetic materials |
| US6878168B2 (en) * | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
| US6752828B2 (en) | 2002-04-03 | 2004-06-22 | Scimed Life Systems, Inc. | Artificial valve |
| US7007698B2 (en) * | 2002-04-03 | 2006-03-07 | Boston Scientific Corporation | Body lumen closure |
| US9101536B2 (en) * | 2002-08-06 | 2015-08-11 | Matrix Medical Llc | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
| US8349348B2 (en) * | 2002-08-06 | 2013-01-08 | Matrix Medical, Llc | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same |
| JP4966494B2 (en) * | 2002-08-06 | 2012-07-04 | マトリックス メディカル エルエルシー | Biocompatible phase-convertible proteinaceous composition and methods for making and using the same |
| US10098981B2 (en) | 2002-08-06 | 2018-10-16 | Baxter International Inc. | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
| AU2003285943B2 (en) * | 2002-10-24 | 2008-08-21 | Boston Scientific Limited | Venous valve apparatus and method |
| US20040153145A1 (en) * | 2002-11-26 | 2004-08-05 | Clemson University | Fixation method for bioprostheses |
| US7189259B2 (en) * | 2002-11-26 | 2007-03-13 | Clemson University | Tissue material and process for bioprosthesis |
| US6945957B2 (en) * | 2002-12-30 | 2005-09-20 | Scimed Life Systems, Inc. | Valve treatment catheter and methods |
| US7474722B1 (en) * | 2003-03-21 | 2009-01-06 | D2Audio Corporation | Systems and methods for sample rate conversion using multiple rate estimate counters |
| US7380163B2 (en) * | 2003-04-23 | 2008-05-27 | Dot Hill Systems Corporation | Apparatus and method for deterministically performing active-active failover of redundant servers in response to a heartbeat link failure |
| US7129210B2 (en) * | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
| US7854761B2 (en) * | 2003-12-19 | 2010-12-21 | Boston Scientific Scimed, Inc. | Methods for venous valve replacement with a catheter |
| US8128681B2 (en) | 2003-12-19 | 2012-03-06 | Boston Scientific Scimed, Inc. | Venous valve apparatus, system, and method |
| US7566343B2 (en) | 2004-09-02 | 2009-07-28 | Boston Scientific Scimed, Inc. | Cardiac valve, system, and method |
| US20060173490A1 (en) | 2005-02-01 | 2006-08-03 | Boston Scientific Scimed, Inc. | Filter system and method |
| US7854755B2 (en) * | 2005-02-01 | 2010-12-21 | Boston Scientific Scimed, Inc. | Vascular catheter, system, and method |
| US7878966B2 (en) * | 2005-02-04 | 2011-02-01 | Boston Scientific Scimed, Inc. | Ventricular assist and support device |
| US7670368B2 (en) * | 2005-02-07 | 2010-03-02 | Boston Scientific Scimed, Inc. | Venous valve apparatus, system, and method |
| US7780722B2 (en) * | 2005-02-07 | 2010-08-24 | Boston Scientific Scimed, Inc. | Venous valve apparatus, system, and method |
| US20060195183A1 (en) * | 2005-02-18 | 2006-08-31 | The Cleveland Clinic Foundation | Apparatus and methods for replacing a cardiac valve |
| US7867274B2 (en) | 2005-02-23 | 2011-01-11 | Boston Scientific Scimed, Inc. | Valve apparatus, system and method |
| US7579381B2 (en) | 2005-03-25 | 2009-08-25 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
| US7722666B2 (en) * | 2005-04-15 | 2010-05-25 | Boston Scientific Scimed, Inc. | Valve apparatus, system and method |
| EP1893131A1 (en) * | 2005-04-20 | 2008-03-05 | The Cleveland Clinic Foundation | Apparatus and method for replacing a cardiac valve |
| US8012198B2 (en) | 2005-06-10 | 2011-09-06 | Boston Scientific Scimed, Inc. | Venous valve, system, and method |
| US7569071B2 (en) | 2005-09-21 | 2009-08-04 | Boston Scientific Scimed, Inc. | Venous valve, system, and method with sinus pocket |
| US7658706B2 (en) * | 2005-12-05 | 2010-02-09 | Rti Biologics, Inc. | Vascular graft sterilization and decellularization |
| US7799038B2 (en) * | 2006-01-20 | 2010-09-21 | Boston Scientific Scimed, Inc. | Translumenal apparatus, system, and method |
| WO2008002767A1 (en) * | 2006-06-29 | 2008-01-03 | Mayo Foundation For Medical Education And Research | Genetically modified heart valve xenografts |
| WO2008073582A2 (en) | 2006-10-27 | 2008-06-19 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
| US8142805B1 (en) | 2006-11-06 | 2012-03-27 | Clemson University Research Foundation | Implantable devices including fixed tissues |
| WO2008091493A1 (en) | 2007-01-08 | 2008-07-31 | California Institute Of Technology | In-situ formation of a valve |
| WO2008089365A2 (en) * | 2007-01-19 | 2008-07-24 | The Cleveland Clinic Foundation | Method for implanting a cardiovascular valve |
| US20080269877A1 (en) * | 2007-02-05 | 2008-10-30 | Jenson Mark L | Systems and methods for valve delivery |
| WO2008097589A1 (en) | 2007-02-05 | 2008-08-14 | Boston Scientific Limited | Percutaneous valve, system, and method |
| US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
| US9360489B2 (en) | 2007-06-11 | 2016-06-07 | Sutter Bay Hospitals | Method and kit for dynamic gene expression monitoring |
| US8828079B2 (en) * | 2007-07-26 | 2014-09-09 | Boston Scientific Scimed, Inc. | Circulatory valve, system and method |
| US8357387B2 (en) | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
| US7892276B2 (en) * | 2007-12-21 | 2011-02-22 | Boston Scientific Scimed, Inc. | Valve with delayed leaflet deployment |
| US20090171456A1 (en) * | 2007-12-28 | 2009-07-02 | Kveen Graig L | Percutaneous heart valve, system, and method |
| US9119714B2 (en) * | 2008-10-29 | 2015-09-01 | The Regents Of The University Of Colorado, A Body Corporate | Shape memory polymer prosthetic medical device |
| US20100261662A1 (en) * | 2009-04-09 | 2010-10-14 | Endologix, Inc. | Utilization of mural thrombus for local drug delivery into vascular tissue |
| NZ624106A (en) * | 2009-04-29 | 2015-12-24 | Cleveland Clinic Foundation | Apparatus and method for replacing a diseased cardiac valve |
| EP2448522A4 (en) * | 2009-07-02 | 2018-01-31 | The Cleveland Clinic Foundation | Apparatus and method for replacing a diseased cardiac valve |
| FR2951549B1 (en) | 2009-10-15 | 2013-08-23 | Olivier Schussler | PROCESS FOR OBTAINING IMPLANTABLE MEDICAL BIOPROTHESES |
| US9211361B2 (en) * | 2010-03-15 | 2015-12-15 | Kemal Schankereli | Thin collagen tissue for medical device applications |
| BR112012023769B1 (en) | 2010-03-23 | 2020-11-10 | Edwards Lifesciences Corporation | method for preparing bioprosthetic tissue membrane material |
| WO2011139488A2 (en) | 2010-05-06 | 2011-11-10 | Mayo Foundation For Medical Education And Research | Methods and materials for reducing cardiac xenograft rejection |
| US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
| US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
| US9358107B2 (en) | 2011-06-30 | 2016-06-07 | Edwards Lifesciences Corporation | Systems, dies, and methods for processing pericardial tissue |
| US9668859B2 (en) | 2011-08-05 | 2017-06-06 | California Institute Of Technology | Percutaneous heart valve delivery systems |
| CN102499993B (en) * | 2011-11-01 | 2014-01-15 | 上海微创医疗器械（集团）有限公司 | Method for preparing edge rigidized artificial biological valve |
| US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
| WO2014144247A1 (en) | 2013-03-15 | 2014-09-18 | Arash Kheradvar | Handle mechanism and functionality for repositioning and retrieval of transcatheter heart valves |
| US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
| US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
| US10631968B2 (en) | 2017-03-06 | 2020-04-28 | Edwards Lifesciences Corporation | Humidity-management packaging systems and methods |
| WO2018222434A1 (en) | 2017-05-31 | 2018-12-06 | Edwards Lifesciences Corporation | Collagen fibers and articles formed therefrom |
| US11103619B2 (en) | 2018-08-30 | 2021-08-31 | Efstathios-Andreas AGATHOS | Anticalcification treatment for impantable biological tissues using calcitonin |
| EP3852683A1 (en) | 2018-11-01 | 2021-07-28 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
| EP3920849A1 (en) | 2019-02-04 | 2021-12-15 | Medtronic, Inc. | Balloon expandable frame for transcatheter implantation of a cardiac valve prosthesis |
| WO2020236520A1 (en) | 2019-05-17 | 2020-11-26 | Medtronic, Inc. | Supra annular tapered balloon expandable stent for transcatheter implantation of a cardiac valve prosthesis |
| CR20220339A (en) | 2019-12-12 | 2022-11-09 | Edwards Lifesciences Corp | Hybrid annuloplasty ring |
| CN111588909A (en) * | 2020-02-24 | 2020-08-28 | 科凯(南通)生命科学有限公司 | Anti-calcification method for biomedical material |
| CN115350332A (en) * | 2022-09-01 | 2022-11-18 | 晨兴(南通)医疗器械有限公司 | Preparation method of anti-calcification biological valve material and anti-calcification biological valve material |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2393580A (en) | 1942-03-31 | 1946-01-22 | Edwin C Weiskopf | Method of preparing tissue |
| DE1063330B (en) | 1955-11-01 | 1959-08-13 | Dr Med Norman Rosenberg | Substances for foreign transplants |
| US3093439A (en) | 1961-07-05 | 1963-06-11 | Johnson & Johnson | Process for preparing tanned collagenous material with dialdehyde starch |
| US3961097A (en) | 1971-10-28 | 1976-06-01 | Gravlee Jr Joseph F | Method of preparing tissue for microscopic examination |
| US4050893A (en) | 1974-07-22 | 1977-09-27 | Hancock Laboratories, Inc. | Arrangement for preparing natural tissue for implantation |
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| US4082507A (en) | 1976-05-10 | 1978-04-04 | Sawyer Philip Nicholas | Prosthesis and method for making the same |
| US4239492A (en) | 1979-06-14 | 1980-12-16 | Beisang Arthur A | Method of preparing vascular grafts of human and other umbilical cord origins for tissue ingrowth |
| US4378224A (en) * | 1980-09-19 | 1983-03-29 | Nimni Marcel E | Coating for bioprosthetic device and method of making same |
| DE3042860A1 (en) | 1980-11-13 | 1982-06-09 | Heyl & Co Chemisch-Pharmazeutische Fabrik, 1000 Berlin | COLLAGEN PREPARATIONS, METHODS FOR THEIR PRODUCTION AND THEIR USE IN HUMAN AND VETERINE MEDICINE |
| US4323358A (en) | 1981-04-30 | 1982-04-06 | Vascor, Inc. | Method for inhibiting mineralization of natural tissue during implantation |
| IN157379B (en) | 1981-04-30 | 1986-03-15 | Extracorporeal Med Spec | |
| US4350492A (en) | 1981-08-24 | 1982-09-21 | Vascor, Inc. | Method for preparing tissue heart valve |
| FR2523810B1 (en) | 1982-03-23 | 1988-11-25 | Carpentier Alain | ORGANIC GRAFT FABRIC AND PROCESS FOR ITS PREPARATION |
| US4481009A (en) * | 1982-05-13 | 1984-11-06 | American Hospital Supply Corporation | Polymer incorporation into implantable biological tissue to inhibit calcification |
| US4405327A (en) | 1982-08-25 | 1983-09-20 | Extracorporeal Medical Specialties, Inc. | Method for inhibiting mineralization of natural tissue during implantation |
| US4402697A (en) | 1982-08-25 | 1983-09-06 | Extracorporeal Medical Specialties, Inc. | Method for inhibiting mineralization of natural tissue during implantation |
| JPS60500014A (en) * | 1982-11-12 | 1985-01-10 | バツクスター トラベノル ラボラトリーズ インコーポレーテツド | Chemical sterilization of biological tissue ready for transplantation |
| US4885005A (en) | 1982-11-12 | 1989-12-05 | Baxter International Inc. | Surfactant treatment of implantable biological tissue to inhibit calcification |
| EP0126743B1 (en) | 1982-11-12 | 1989-04-12 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Surfactant treatment of implantable biological tissue to inhibit calcification |
| US5215541A (en) * | 1982-11-12 | 1993-06-01 | Baxter International Inc. | Surfactant treatment of implantable biological tissue to inhibit calcification |
| US4713446A (en) * | 1985-09-06 | 1987-12-15 | Minnesota Mining And Manufacturing Company | Viscoelastic collagen solution for ophthalmic use and method of preparation |
| US4729139A (en) * | 1985-11-05 | 1988-03-08 | Baxter Travenol | Selective incorporation of a polymer into implantable biological tissue to inhibit calcification |
| US4770665A (en) * | 1985-11-05 | 1988-09-13 | American Hospital Supply Corporation | Elastomeric polymer incorporation into implantable biological tissue to inhibit calcification |
| US4786287A (en) | 1986-10-10 | 1988-11-22 | Baxter Travenol Laboratories | Process for decreasing residual aldehyde levels in implantable bioprosthetic tissue |
| US4798611A (en) * | 1986-10-14 | 1989-01-17 | Hancock Jaffe Laboratories | Enhancement of xenogeneic tissue |
| US4800603A (en) * | 1987-01-30 | 1989-01-31 | Jaffe Norman R | Tissue fixation with vapor |
| US4994237A (en) * | 1987-10-02 | 1991-02-19 | The Beth Israel Hospital Association | Microwave preservation of bioprostheses |
| US4976733A (en) | 1988-02-03 | 1990-12-11 | Biomedical Design, Inc. | Prevention of prosthesis calcification |
| EP0364517B1 (en) | 1988-02-03 | 1994-04-06 | Biomedical Design, Inc. | Prevention of prosthesis calcification |
| US5746775A (en) | 1988-04-01 | 1998-05-05 | The Board Of Regent6S Of The University Of Michigan | Method of making calcification-resistant bioprosthetic tissue |
| EP0362438A1 (en) | 1988-06-21 | 1990-04-11 | Mathilde Elisabeth Boon | Microwave treatment of xenogeneic cartilage transplants |
| SU1651890A1 (en) * | 1988-06-22 | 1991-05-30 | Институт сердечно-сосудистой хирургии им.А.Н.Бакулева | Method for treatment of heart valve bioprothesis |
| US5264214A (en) * | 1988-11-21 | 1993-11-23 | Collagen Corporation | Composition for bone repair |
| US5171273A (en) * | 1989-01-13 | 1992-12-15 | University Of Medicine And Dentistry Of New Jersey | Synthetic collagen orthopaedic structures such as grafts, tendons and other structures |
| US5002566A (en) | 1989-02-17 | 1991-03-26 | Baxter International Inc. | Calcification mitigation of bioprosthetic implants |
| US5068086A (en) | 1990-06-12 | 1991-11-26 | Raytheon Company | Method and apparatus for batch fixating tissue specimens |
| US5104405A (en) | 1991-02-21 | 1992-04-14 | The University Of Southern California | Process for improving the biostability of tissue implant devices and bioprosthetic implants so produced |
| US5476516A (en) * | 1992-03-13 | 1995-12-19 | Albert Einstein College Of Medicine Of Yeshiva University | Anticalcification treatment for aldehyde-tanned biological tissue |
| US5283256A (en) * | 1992-07-22 | 1994-02-01 | Merck & Co., Inc. | Cholesterol-lowering agents |
| US5437287A (en) * | 1992-08-17 | 1995-08-01 | Carbomedics, Inc. | Sterilization of tissue implants using iodine |
| US5447536A (en) * | 1994-02-17 | 1995-09-05 | Biomedical Design, Inc. | Method for fixation of biological tissue |
| ES2219660T3 (en) | 1994-03-14 | 2004-12-01 | Cryolife, Inc | METHODS OF PREPARATION OF FABRICS FOR IMPLEMENTATION. |
| US5595571A (en) | 1994-04-18 | 1997-01-21 | Hancock Jaffe Laboratories | Biological material pre-fixation treatment |
| EP0804255B1 (en) | 1994-07-29 | 2001-10-04 | Edwards Lifesciences Corporation | Methods for treating implantable biological tissues to mitigate the calcification thereof |
| US5931969A (en) * | 1994-07-29 | 1999-08-03 | Baxter International Inc. | Methods and apparatuses for treating biological tissue to mitigate calcification |
| US5674298A (en) * | 1994-10-21 | 1997-10-07 | The Board Of Regents Of The University Of Michigan | Calcification-resistant bioprosthetic tissue and methods of making same |
| US5782931A (en) * | 1996-07-30 | 1998-07-21 | Baxter International Inc. | Methods for mitigating calcification and improving durability in glutaraldehyde-fixed bioprostheses and articles manufactured by such methods |
| EP0986405B1 (en) * | 1997-02-10 | 2003-05-02 | Biomedical Design, Inc. | Method of sterilization |
| US5891196A (en) * | 1997-04-16 | 1999-04-06 | Baxter International Inc. | Method for actively binding heparin to crosslinked biological tissues |
| US6008292A (en) * | 1997-12-02 | 1999-12-28 | Baxter International Inc. | Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials |
| BE1012763A3 (en) | 1999-06-25 | 2001-03-06 | Wiele Michel Van De Nv | Yarn pool selection system grijperaxminsterweefmachines. |
-
1995
- 1995-07-25 EP EP95931511A patent/EP0804255B1/en not_active Expired - Lifetime
- 1995-07-25 JP JP50681296A patent/JP3797673B2/en not_active Expired - Lifetime
- 1995-07-25 CA CA002196165A patent/CA2196165C/en not_active Expired - Lifetime
- 1995-07-25 DE DE69523074T patent/DE69523074T2/en not_active Expired - Lifetime
- 1995-07-25 WO PCT/US1995/010001 patent/WO1996004028A1/en active IP Right Grant
-
1996
- 1996-12-12 US US08/764,821 patent/US6561970B1/en not_active Expired - Lifetime
-
2003
- 2003-02-05 US US10/359,479 patent/US7029434B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0804255B1 (en) | 2001-10-04 |
| WO1996004028A1 (en) | 1996-02-15 |
| JP3797673B2 (en) | 2006-07-19 |
| US6561970B1 (en) | 2003-05-13 |
| US7029434B2 (en) | 2006-04-18 |
| DE69523074T2 (en) | 2002-06-06 |
| JPH10507102A (en) | 1998-07-14 |
| US20040030405A1 (en) | 2004-02-12 |
| EP0804255A1 (en) | 1997-11-05 |
| DE69523074D1 (en) | 2001-11-08 |
| CA2196165A1 (en) | 1996-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2196165C (en) | Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods | |
| US6277555B1 (en) | Compliant dehydrated tissue for implantation and process of making the same | |
| US4994237A (en) | Microwave preservation of bioprostheses | |
| JP4555570B2 (en) | Treatment of bioprosthetic tissue to reduce post-transplant calcification | |
| US6214055B1 (en) | Method and kit for rapid preparation of autologous tissue medical devices | |
| US8236241B2 (en) | Treating biological tissues to mitigate post-implantation calcification | |
| US5902338A (en) | Anterior cruciate ligament heterograft | |
| Grimm et al. | Biocompatibility of aldehyde-fixed bovine pericardium: an in vitro and in vivo approach toward improvement of bioprosthetic heart valves | |
| US5882850A (en) | Method for reducing calcification of biological tissue used implantable bioprostheses | |
| CA2323866A1 (en) | Bone xenografts | |
| US6972041B1 (en) | Bone xenografts | |
| Kiraly et al. | Natural tissue as a biomaterial | |
| US9555162B2 (en) | Phospholipid reduction in biological tissue | |
| WEBER | GENERAL SURGICAL PROBLEMS OF TISSUE TRANSPLANTATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150727 |